Hold DHR at 70-75% weight; no chase at elevated levels; await Zone A/B pullback or breakout above $242.80
Maintain DHR at 70-75% benchmark weight with trailing stop at $218.96; do not initiate fresh capital at $227 given structurally unfavorable 0.53R risk/reward math, elevated RSI at 71.27, and price stretched +12.9% above 200 SMA; half-size positions permitted only on confirmed pullback to Zone B ($218-$220) or full sizing at Zone A ($206-$212) with bullish confirmation or breakout above $242.80 on volume; upgrade to Overweight requires any two of four specified triggers; all three analyst frameworks converge on HOLD binding decision.
| Position | Action |
|---|---|
| Existing position at 70-75% benchmark weight | Apply tightened trailing stop at $218.96 (10 EMA) |
| Zone B pullback ($218-$220) with confirmed reversal candle | Half-size starter positions permitted |
| Zone A entry ($206-$212) with bullish confirmation OR volume-confirmed breakout above $242.80 | Full sizing authorized |
| Current price level at $227 with RSI 71.27, +12.9% above 200 SMA, 94% of 52-week high | Do NOT initiate fresh capital |
DHR is a defensive, cash-generative compounder mid-cycle in a structural EPS inflection that the market has only partially priced, warranting an aggressive BUY at current levels rather than waiting for a pullback that may not materialize with meaningful depth.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $218.96 | bullish |
| 50 SMA | $206.36 | bullish |
| 200 SMA | $201.36 | bullish |
| RSI | 71.27 | neutral |
| MACD | 4.82 | bullish |
| MACD Signal | 3.07 | bullish |
| MACD Histogram | +1.75 | bullish |
| Bollinger Upper Band | $228.10 | neutral |
| Bollinger Middle Band | $211.96 | neutral |
| Bollinger Lower Band | $195.82 | neutral |
| ATR | $5.79 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Entry at $206-$212 with bullish confirmation
Then: Full sizing authorized
↩ rebuts: “RSI 71.27 overbought; trend exhausted”
EV: +$33.68 to $260+ (T1 $233.68, T2 $241.20, T3 $260+) · concedes: Bear concedes structural growth thesis (label-free detection, single-use bioreactors, bioprocessing tailwinds); Iran geopolitics is at most a 5-8% pullback opportunity, not a structural headwind; RSI 71.27 is technically overbought but typical of strong uptrends per technical report
DHR is a "HOLD with downside skew" at $227 because the stock is overextended, the EPS recovery is buyback-engineered rather than organic, valuation is stretched relative to fundamentals and the risk-free rate, and multiple compression risk is asymmetric.
· concedes: DHR is still a quality compounder with $5.26B in FCF, a bulletproof balance sheet, and a defensive business model; Existing holders should not panic-sell into a confirmed uptrend; If the stock pulls back to the 50 SMA at $206, that would be a 9% better entry on a confirmed uptrend with reset oscillators; The company may deserve a 'BUY' rating at $206 rather than at $227
→ vs conservative: Zone B ($218-220) and Zone A ($206-212) represent 3-10% downside to capture 3-8% upside—this is the opposite of asymmetric risk-reward; expected value favors entry at $227
→ vs conservative: RSI 71.27 'approaching overbought' argument is 'tired'—RSI can run 70-80 for weeks in strong uptrends; no current divergence like January 2026
→ vs conservative: ROE depressed at 7.6% due to bloated equity base, not broken business; buyback EPS accretion is a 'feature, not a flaw' of the model
→ vs conservative: FCF yield 3.3% vs 10-year 4% comparison is 'intellectually lazy'—forward FCF yield is 4.5-5% and growing, unlike static Treasury coupon
→ vs conservative: $241.20 upside cap ignores that DHR previously ran through 52-week highs in late July-August; history shows 10-20% extension beyond prior resistance
→ vs neutral: Buyback-engineered EPS growth is 'mathematically accretive' at $9B/24 months when stock at $227; market doesn't penalize per-share value improvement
→ vs conservative: 0.81 beta is a 'signal' for defensive outperformance in uncertain macro, not a reason to wait; higher-for-longer rates favor quality defensives
| VWMA (20-period) | $213.63 | bullish |
| Volume | 4.9M | bullish |
Support: 195.82 · 201.36 · 206.36 · 211.96 · 218.96 | Resistance: 228.1 · 233.68 · 241.2
The overall technical picture is bullish across all timeframes with a confirmed golden-cross regime (50 SMA above 200 SMA) and price closing $25.97 above the 200 SMA. Momentum is positive with MACD having completed a fresh bullish cross in early September and RSI in the upper quadrant at 71.27. Price is currently riding the upper Bollinger band at $228.10, which signals strength but also overextension. Volatility is normal (ATR $5.79) and volume is modestly above average at 4.9M, confirming the rally. Key support layers are at $211.96 (middle band), $206.36 (50 SMA), and $201.36 (200 SMA), while resistance sits at $228.10, $233.68, and $241.20. The recommendation is HOLD—existing holders should use a trailing stop near the 10 EMA ($218.96), and new entries should await either a confirmed breakout above $228 with volume or a pullback to the $218–$212 zone.
Market Capitalization
$159.81B
Beta
0.808
52-Week Trading Range
$160.93 – $242.80
50-Day MA
$205.89
200-Day MA
$201.80
Revenue (2025)
$24.57B
Revenue (2024)
$23.88B
Revenue (2023)
$23.89B
Revenue (2022)
$26.64B
Gross Profit (2025)
$14.52B
Operating Income (2025)
$4.69B
Net Income (2025)
$3.61B
Diluted EPS (TTM)
$5.61
Diluted EPS (2025)
$5.05
Diluted EPS (2024)
$5.29
Diluted EPS (2023)
$6.38
Diluted EPS (2022)
$9.66
Forward EPS
$9.30
EBITDA (2025)
$6.95B
EBITDA (2024)
$7.28B
EBITDA (2023)
$7.50B
EBITDA (2022)
$9.48B
Operating Cash Flow (2025)
$6.42B
Operating Cash Flow (2024)
$6.69B
Operating Cash Flow (2023)
$7.16B
Free Cash Flow (2025)
$5.26B
Free Cash Flow (2024)
$5.30B
Free Cash Flow (2023)
$5.78B
Free Cash Flow (2022)
$7.40B
Capital Expenditure (2025)
$1.16B
R&D Investment (2025)
$1.60B
R&D Investment (2023)
$1.50B
Total Assets (2025)
$83.46B
Total Equity (2025)
$52.53B
Total Debt (2025)
$19.70B
Cash & Equivalents (2025)
$4.62B
Net Debt (2025)
$13.80B
Goodwill + Intangibles (2025)
$60.97B
Working Capital (2025)
$5.95B
Current Ratio (2025)
1.65
Treasury Stock (2025)
$11.35B
Share Repurchases (2024-25)
$9.07B
Dividends Paid (2025)
$0.88B
Dividend Yield
0.71%
P/E (TTM)
40.52×
Forward P/E
24.45×
PEG Ratio
1.34
P/B
3.04
EV/EBITDA (TTM)
~22×
FCF Yield
~3.3%
Return on Equity (ROE)
7.6%
Return on Assets (ROA)
3.95%
Gross Margin
58.8%
Operating Margin (TTM)
19.77%
Net Margin (TTM)
15.95%
Share Count (2025)
716M
Strengths
Concerns
Danaher presents a classic high-quality compounder at a cyclical valuation trough, with 2025 representing the inflection point after three years of COVID normalization compressed revenue from $26.6B to $23.9B and operating margins from 28.3% to 19.1%. The investment case hinges on consensus expectations for near-doubling of EPS from $5.61 TTM to $9.30, driven by bioprocessing tailwinds from GLP-1 manufacturing capacity expansion (Cytiva), Cepheid diagnostic volume recovery, and continued mechanical EPS accretion from aggressive share buybacks. However, the forward P/E of 24.4× already bakes in this recovery, leaving limited upside without continued execution, and the intangible-heavy balance sheet ($61B in goodwill) creates residual impairment risk.
Macro: Higher-for-longer rates regime dominates: Polymarket prices 97% probability of no Fed rate cuts in 2026 ($8.6M volume). Treasury yields are climbing, pressuring equity multiples broadly. US–Iran tensions elevated with 14% invasion probability priced ($70M volume). Soft-landing remains base case with 8% US recession odds by YE 2026. Dow, S&P 500, and Nasdaq in red Monday 9/28 as yields rise; defensive/healthcare rotation theme plausible.